Dapagliflozin Reduces MACE, CV Death in Patients With T2D and Prior MI
Dapagliflozin reduces MACE, CV death, and risk for heart failure hospitalization in patients with type 2 diabetes and prior MI.
Myocardial Infarction
Dapagliflozin reduces MACE, CV death, and risk for heart failure hospitalization in patients with type 2 diabetes and prior MI.
